RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
  Bladder
  Blood
   Multiple Myeloma
   Non-Hodgkin's Lymphoma
  Bone Cancer
  Brain
  Breast Cancer
  Carcinogens
  Cervical Cancer
  Colon
  Endometrial
  Esophageal
  Gastric Cancer
  Liver Cancer
  Lung
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Skin
  Testicular Cancer
  Therapy
  Thyroid
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Blood Channel

subscribe to Blood newsletter
Latest Research : Cancer : Blood

   EMAIL   |   PRINT
Test Vaccine Effective for Follicular Lymphoma

Nov 11, 2005 - 12:58:00 AM
Stanford University developed an idiotypical vaccine in the seventies in animals and applied it to humans 15 years ago. In 1992 its biological efficacy was tested: it is capable of stimulating the human immune system. In 1999 Dr. Bendandi and other scientists at the US National Cancer Institute demonstrated that this biological efficacy was also clinical. According to the University of Navarre researcher, the vaccine-stimulated immune system itself is capable of killing some tumour cells that had resisted quimiotherapy. It remains to be demonstrated that this result provides a real benefit to the patient.

 
[RxPG] A team of researchers has demonstrated the clinical efficacy and benefits of a vaccine for a type of blood cancer, follicular lymphoma, amongst first time relapse patients. Specialists from two University of Navarre centres – the University Hospital and the Research Centre for Applied Medicine (CIMA) - have worked jointly since 2001 on the research. According to Dr. Maurizio Bendandi, the team leader, it is the first time that a vaccine against a type of cancer has been able to change the history of the illness. In Spain more than 5000 persons over 40 are annually diagnosed with this type of cancer. Follicular lymphoma is a tumour of the lymphatic system the cells of which present a surface protein – in fact, an immunoglobuline - that can be used as a target. The vaccine, known as idiotypical, is produced from this protein and its aim is to provoke a reaction from the immune system of the patient. Normally the patient does not react against the protein of the tumour given that, as it is a known element, its immune system does not combat it. By means of laboratory techniques we have managed to adhere to the target protein another protein called KLH, obtained from a mollusc. In this way we managed to get the tumoural protein also to be recognised as foreign.

In the case of follicular lymphoma, this protein is a specific tumour antigen. It is postulated that there are also antigens in other tumours but, for the moment, none has been identified solely and exclusively in the tumour cells and, thus, a vaccine against these would also be damaging to healthy tissues.

Stanford University developed an idiotypical vaccine in the seventies in animals and applied it to humans 15 years ago. In 1992 its biological efficacy was tested: it is capable of stimulating the human immune system. In 1999 Dr. Bendandi and other scientists at the US National Cancer Institute demonstrated that this biological efficacy was also clinical. According to the University of Navarre researcher, the vaccine-stimulated immune system itself is capable of killing some tumour cells that had resisted quimiotherapy. It remains to be demonstrated that this result provides a real benefit to the patient.

With the research work carried out at CIMA and the University Hospital it is known that 50% of the patients treated with quimiotherapy relapse within13 months. Moreover, the duration of the response time tends to be shorter between relapses than between the previous ones.

The research involved 25 patients over the last four and a half years. Of these, 4 patients did not respond to the vaccine and relapsed in the expected time, with another 3 the study of their illness is yet to finish and 18 responded satisfactorily. None of these 18 has relapsed over the two years vaccination.

This is the first study of this kind or design to investigate the efficacy of the vaccine in patients suffering relapse, although other clinical trials are being undertaken at two centres in the United States.

The vaccine, administered subcutaneously, is especially useful as a complement to quimiotherapy. There have been attempts to apply the vaccine as a first treatment but the results have not been satisfactory.

In general terms, the procedure followed with patients at the University Hospital was to give them conventional quimiotherapy for 6 months in order to reduce the size of the tumour as much as possible. This was followed by a rest period of between 3 and 6 months in order to reconstitute the immune system. Finally, the vaccine was innoculated every month for three or four months, whereupon the frequency of this dosage was gradually reduced.



Publication: University Hospital and the Research Centre for Applied Medicine (CIMA), University of Navarre, Spain
On the web: www.unav.es/cun 

Advertise in this space for $10 per month. Contact us today.


Related Blood News


Subscribe to Blood Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)